A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation

Bone Marrow Transplantation
J MooreS Milliken

Abstract

Haematopoietic stem cell transplantation (HSCT) has been used recently as an effective therapy in patients with resistant rheumatoid arthritis (RA). Although disease control occurs in the majority of cases, recurrence is common, often coinciding with B-cell reconstitution. We hypothesized that Rituximab, a monoclonal anti-CD20 antibody, would have activity in this group of patients. We treated 10 RA patients (8F:2M, median age 46.5 years), who had recurrent disease post HSCT. All patients received two doses of Rituximab 1 g, 2 weeks apart with no major adverse sequelae and were followed for 12 months. A total of eight out of 10 patients experienced major clinical responses as measured by the American College of Rheumatology (ACR) criteria, with 50-70% improvement in disease parameters. Responses were equivalent to previous responses attained with HSCT. Disease responses were maximal at 4-8 months post Rituximab and correlated with B-cell lymphopenia and a reduction of rheumatoid factor titre. Disease recurrence occurred in 6/9 responders within 12 months and four patients were subsequently retreated, with major responses again attained. This study provides further evidence that B-cell depletion leads to a significant improvemen...Continue Reading

References

Sep 26, 1992·Lancet·J D IsaacsH Waldmann
Jan 1, 1989·Acta Neurologica Scandinavica·B M UitdehaagO R Hommes
Nov 1, 1985·Annals of the Rheumatic Diseases·V NeumannV Wright
Aug 2, 2000·Proceedings of the National Academy of Sciences of the United States of America·K KoetzC M Weyand
Sep 14, 2002·Annals of the Rheumatic Diseases·M J LeandroG Cambridge

❮ Previous
Next ❯

Citations

Jun 2, 2006·Springer Seminars in Immunopathology·Paul Hasler
Feb 14, 2008·Clinical Reviews in Allergy & Immunology·Claudio GalarzaJuan-Manuel Anaya
Nov 21, 2007·Annals of the Rheumatic Diseases·D E FurstM E Weinblatt
Mar 25, 2008·Therapeutics and Clinical Risk Management·Adam Bryant, John Moore
Aug 6, 2013·Calcified Tissue International·Sarah E WytheNicole J Horwood
Sep 13, 2012·Clinical & Developmental Immunology·Alberto M Marmont du Haut Champ
Sep 6, 2013·Immunological Investigations·Nicole J Horwood
Oct 30, 2008·Autoimmunity·J A SnowdenA G Wilson
Aug 25, 2010·Best Practice & Research. Clinical Rheumatology·Alan Tyndall, Jacob M van Laar
Sep 19, 2006·Best Practice & Research. Clinical Rheumatology·J C W EdwardsM J Leandro
Aug 22, 2006·Autoimmunity Reviews·James S W KongM Eric Gershwin
Aug 23, 2005·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Chinh N TranDavid A Fox
Oct 27, 2007·Seminars in Hematology·Jakob Passweg, Alan Tyndall
Oct 27, 2005·The Annals of Pharmacotherapy·Kelly M Summers, Denise R Kockler
Nov 27, 2008·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Rosemary AdamsonDavid P D'Cruz
Aug 2, 2019·Clinical Rheumatology·Soheil TavakolpourArash Jafarieh
Jan 19, 2006·Rheumatology·O M R WestwoodF C Hay
Feb 18, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jie-Yu ChungFrank Alderuccio
Feb 13, 2019·Rheumatology·Femke C C van Rhijn-BrouwerJacob M van Laar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.